NCT04203901 - Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions

Advanced Renal Cell Carcinoma

Interventions

BIOLOGICAL

CMN-001

Autologous Dendritic Cell Therapy

BIOLOGICAL

Nivolumab+Ipilimumab

anti-PD-1 and anti-CTLA4 antibodies

DRUG

Lenvatinib+Everolimus

TKI+mTOR inhibitors

Trial Locations (9)

Westchester Medical Center, Valhalla

SUNY Upstate Medical University, Syracuse

UPMC Hillman Cancer Center, Pittsburgh

West Virginia University Cancer Institute, Morgantown

Emory University, Atlanta

Moffitt Cancer Center, Tampa

Mayo Clinic, Rochester

Houston Methodist, Houston

MD Anderson Cancer Center, Houston